NASDAQ:CODX Co-Diagnostics (CODX) Stock Price, News & Analysis $0.25 -0.01 (-4.02%) Closing price 08/1/2025 03:56 PM EasternExtended Trading$0.25 0.00 (-0.89%) As of 08/1/2025 07:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Co-Diagnostics Stock (NASDAQ:CODX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Co-Diagnostics alerts:Sign Up Key Stats Today's Range$0.24▼$0.2650-Day Range$0.23▼$0.3052-Week Range$0.23▼$2.23Volume1.05 million shsAverage Volume1.41 million shsMarket Capitalization$8.33 millionP/E RatioN/ADividend YieldN/APrice Target$5.50Consensus RatingBuy Company Overview Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah. Read More Co-Diagnostics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks79th Percentile Overall ScoreCODX MarketRank™: Co-Diagnostics scored higher than 79% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingCo-Diagnostics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageCo-Diagnostics has received no research coverage in the past 90 days.Read more about Co-Diagnostics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Co-Diagnostics are expected to grow in the coming year, from ($1.22) to ($1.17) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Co-Diagnostics is -0.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Co-Diagnostics is -0.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCo-Diagnostics has a P/B Ratio of 0.15. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Co-Diagnostics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.51% of the outstanding shares of Co-Diagnostics have been sold short.Short Interest Ratio / Days to CoverCo-Diagnostics has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Co-Diagnostics has recently increased by 197.81%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCo-Diagnostics does not currently pay a dividend.Dividend GrowthCo-Diagnostics does not have a long track record of dividend growth. Sustainability and ESG4.4 / 5Environmental Score-1.10 Percentage of Shares Shorted2.51% of the outstanding shares of Co-Diagnostics have been sold short.Short Interest Ratio / Days to CoverCo-Diagnostics has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Co-Diagnostics has recently increased by 197.81%, indicating that investor sentiment is decreasing significantly. News and Social Media1.4 / 5News Sentiment-0.50 News SentimentCo-Diagnostics has a news sentiment score of -0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Co-Diagnostics this week, compared to 1 article on an average week.Search Interest4 people have searched for CODX on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Co-Diagnostics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.40% of the stock of Co-Diagnostics is held by insiders.Percentage Held by InstitutionsOnly 14.99% of the stock of Co-Diagnostics is held by institutions.Read more about Co-Diagnostics' insider trading history. Receive CODX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Co-Diagnostics and its competitors with MarketBeat's FREE daily newsletter. Email Address CODX Stock News HeadlinesCo-Diagnostics, Inc. Announces Second Quarter 2025 Earnings Release Date and WebcastJuly 31 at 9:30 AM | prnewswire.comCo-Diagnostics, Inc. to Host Booth at WHX Kuala Lumpur on July 16-18, 2025July 15, 2025 | finance.yahoo.comBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. August 2 at 2:00 AM | Crypto 101 Media (Ad)Co-Diagnostics, Inc. to Host Booth at WHX Kuala Lumpur on July 16-18, 2025July 15, 2025 | prnewswire.comCODX Co-Diagnostics, Inc. - Seeking AlphaJune 26, 2025 | seekingalpha.comCo-Diagnostics, Inc. to Participate in D. Boral Inaugural Global Conference | CODX Stock NewsMay 14, 2025 | gurufocus.comCo-Diagnostics, Inc. to Participate in D. Boral Inaugural Global ConferenceMay 14, 2025 | gurufocus.comCo-Diagnostics, Inc. to Participate in D. Boral Inaugural Global ConferenceMay 14, 2025 | globenewswire.comSee More Headlines CODX Stock Analysis - Frequently Asked Questions How have CODX shares performed this year? Co-Diagnostics' stock was trading at $0.75 on January 1st, 2025. Since then, CODX stock has decreased by 66.9% and is now trading at $0.2482. How were Co-Diagnostics' earnings last quarter? Co-Diagnostics, Inc. (NASDAQ:CODX) released its quarterly earnings results on Thursday, May, 8th. The company reported ($0.24) earnings per share for the quarter, topping analysts' consensus estimates of ($0.33) by $0.09. The company had revenue of $0.05 million for the quarter, compared to the consensus estimate of $0.38 million. Co-Diagnostics had a negative trailing twelve-month return on equity of 60.16% and a negative net margin of 1,025.45%. Read the conference call transcript. When did Co-Diagnostics IPO? Co-Diagnostics (CODX) raised $9 million in an initial public offering (IPO) on Thursday, July 13th 2017. The company issued 1,300,000 shares at $6.35-$6.75 per share. WallachBeth Capital and Network 1 Securities served as the underwriters for the IPO. How do I buy shares of Co-Diagnostics? Shares of CODX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Co-Diagnostics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Co-Diagnostics investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Moderna (MRNA), Inovio Pharmaceuticals (INO) and Novavax (NVAX). Company Calendar Last Earnings5/08/2025Today8/02/2025Next Earnings (Estimated)8/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical Services Sub-IndustryMedical Equipment Current SymbolNASDAQ:CODX CIK1692415 Webwww.codiagnostics.com Phone(801) 438-1036FaxN/AEmployees100Year FoundedN/APrice Target and Rating Average Price Target for Co-Diagnostics$5.50 High Price Target$10.00 Low Price Target$1.00 Potential Upside/Downside+2,116.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($1.17) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$37.64 million Net Margins-1,025.45% Pretax Margin-1,024.14% Return on Equity-60.16% Return on Assets-52.69% Debt Debt-to-Equity RatioN/A Current Ratio4.43 Quick Ratio4.23 Sales & Book Value Annual Sales$3.91 million Price / Sales2.13 Cash FlowN/A Price / Cash FlowN/A Book Value$1.70 per share Price / Book0.15Miscellaneous Outstanding Shares33,570,000Free Float30,753,000Market Cap$8.33 million OptionableOptionable Beta0.51 Social Links Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:CODX) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Co-Diagnostics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Co-Diagnostics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.